title: [Age-related macular degeneration – a challenge for public health care].
abstract: Age-related macular degeneration (AMD) is the predominant cause of legal blindness in the population over 50 years of age. The disorder shows exponentially increasing prevalence with age, and the late forms with their vision threatening evolution are found in approximately one third of cases. The late AMD may be purely atrophic and so far untreatable. Or it may be neovascular and exudative, for which medical treatment is available, consisting of repetitive intravitreous injections of Anti-VEGF molecules. The treatment is highly effective in blocking the growth of the pathological vessels and allowing resolution of the accompanying edema. Visual improvement is variable but often very meaningful for the patients. However, the final visual level depends mostly on early intervention. Thus, screening for the first signs of neovascular AMD is crucial for the endresult. However, the repetitive intraocular injections are an important burden for the patients. Due to the high patient numbers, the chronic care management with steadily adding new patients is a major challenge for treating institutions. Limited resources may put patients at risk of undertreatment with resulting visual loss. Various strategies have been developed to cope with the burden. In addition, the financial cost is high for the health care system. On the other hand, timely and ongoing treatment is the best investment to achieve meaningful visual improvement, which is extremely important for the quality of life and autonomy of the patients. Side effects of the treatment are limited and mostly procedure related. Systemic side effects are possible but despite the large studies not conclusive. However, care must be taken in cases of high cardiovascular risk, as thromboembolic risk increase may rarely happen. So far unsolved problems include the long term visual results, the degree of reversibility of neovascularization, and the missing treatment options of atrophic AMD. Basic and clinical research on various treatment options for AMD is ongoing, and some additional molecules are expected for the near future, hopefully not only for neovascular AMD but including atrophic AMD as well.
authors.affiliation: 1 Departement für Ophthalmologie, Universitäts-Augenklinik Jules Gonin, Lausanne.
authors.forename: Irmela
authors.initials: I
authors.lastname: Mantel
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D001766:Blindness / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D042241:Early Diagnosis; D019317:Evidence-Based Medicine; D006801:Humans; D008268:Macular Degeneration / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D008403:Mass Screening / Q000379:methods*; D011634:Public Health / Q000639:trends*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors